Abstract: Primary cutaneous B-cell lymphomas (PCBCLs) constitute 25% of all primary cutaneous lymphomas. They present in the skin with no evidence of systemic or extracutaneous disease at the time of diagnosis, after adequate staging. Primary cutaneous B-cell lymphomas differ signifi cantly from their nodal counterparts in relation to both clinical behavior and prognosis. The distinction between primary and secondary B-cell lymphomas is essential for defi ning prognosis/course of action. Such distinction is also very diffi cult to make, since primary and secondary B-cell lymphomas are clinically and histologically indistinguishable. We report the case of a patient with primary cutaneous follicle center lymphoma who underwent surgical excision.
INTRODUCTION
The lymphomas are a group of neoplasms arising from the lymphoreticular system. They are divided into two main groups: Hodgkin's lymphoma (HL) and non-Hodgkin lymphomas (NHL). The latter may be nodal (when primarily involving the lymph nodes) or extranodal. 1 About 30% of NHL involve extranodal tissues. The skin is the second most affected organ (after the gastrointestinal tract), comprising approximately 18% of these lymphomas. 2 Based on their cellular origin and according to the expressed monoclonal antibodies, lymphomas can be divided into T-or B-cell lymphomas. 1, 3 The expression of CD3, CD4, CD8, CD43 or CD45 confi rms their T-cell character. The expression of CD20, in particular, but also of CD79, CD5 and CD10 confi rms their B-cell character.
3 Cutaneous B-cell lymphomas (CBCL) are less frequent than cutaneous T-cell lymphomas, representing about 25% of all cutaneous lymphomas. It shows a slight pREFERENCES for males and an increased incidence with age. 1 CBCL can be primary or secondary. Primary CBCL have a more indolent natural history than secondary CBCL and a good prognosis. They are characterized by having only cutaneous presentation, with no evidence of extracutaneous lesion after adequate staging. They have an identical morphological appearance but different clinical behaviors. We report the case of a patient with primary cutaneous follicle center lymphoma (PCFCCL), the most common type of CBCL, which occurs primarily in the skin and whose clinical manifestations can mimic many other diseases. In our case, the main differential clinical diagnosis was basal cell carcinoma.
CASE REPORT
A 65-year-old white male patient had had an asymptomatic, smooth-surfaced, erythematous nodular lesion of 1.2 cm in diameter, with telangiectasia and progressive growth on the left nasal ala for eight months ( Figure 1 ). The initial diagnostic hypothesis was basal cell carcinoma. Histopathological examination revealed a preserved dermis and epidermis with formation of lymphoid follicles. Lymphocytic cells were identifi ed both in the periphery and center of the follicle (Figure 2 ). Immunohistochemistry was positive for CD20, CD10 and Bcl-6 in cells of the germinal center and negative for Bcl-2, thus confi rming the diagnosis primary cutaneous follicle center lymphoma ( Figure 3 ). Laboratory tests showed normal blood They have a predilection for males and mainly affect adults with an average age of 60 years. Clinically, it manifests itself as solitary or grouped, erythematous to violaceous papules, plaques, nodules or tumors. They rarely ulcerate or exhibit necrosis. The lesions occur mainly on the head, neck and trunk. The differential diagnosis includes infl ammatory lesions such as acne, epidermal inclusion cyst, and lymphoid hyperplasia, and cutaneous malignancies such as basal cell carcinoma. 1, 3 In the case presented here, the fi rst diagnostic hypothesis was basal cell carcinoma. Diagnostic differentiation was carried out by means of histology, immunohistochemistry and staging tests.
The fi ve year survival rate is over 95%. Spread to lymph nodes or internal organs is rare (5%). The recurrence rate is high (about 50%), but there is not a worse prognostic factor and it is usually confi ned to skin.
1,2 Histologically, it presents dermal and subcutaneous proliferation of centrocytes and centroblasts in a follicular and/or diffuse growth pattern. The tumor cells express B-cell markers such as CD20, CD79a, CD10, Bcl-6 and negativity for Bcl-2. 1 For single lesions, as in the case reported here, the fi rst choice of treatment is radiotherapy or surgical excision. 2 Differentiating between primary and secondary skin involvement, through undiagnosed nodal or visceral malignancies, is crucial in addressing CBCL, because of the difference in prognosis and therapeutic options, given that primary and secondary B-cell lymphomas are clinically and histologically indistinguishable. 1, 2, 3, 4 In the past, it was believed that CBCL were invariably secondary. In recent years, however, it has been recognized that CBCL whose primary site is the skin represent a distinct and very important group of extranodal lymphomas. 
